Alkermes Plc (NASDAQ: ALKS) rallied after the company said its mid-stage clinical trial of the drug ALKS 5451, meant to cure depressive disorders, showed it was capable of “significantly reducing” symptoms of depression. The Company said that it carried studies on 142 patients. Based on the outcome of clinical trials, the Company now intends to hold a meeting with the U.S Food and Drug Administration (FDA) and commence later stage studies.
Continue reading Major Movers on April 17; ALKS, CSX, BAC, MAT, AAPL, CAT